LONDON (Alliance News) - Life sciences company Abzena PLC on Monday said its Antitope Ltd subsidiary has extended its collaboration with three research institutes for work on developing HIV vaccines.
Antitope is working with the French National Institute of Health and Medical Research INSERM, the National Health Agency for Research on AIDS and Hepatitis ANRS, and the Baylor Institute for Immunology Research.
INSERM-ANRS and Baylor have developed approaches to HIV vaccines targeting HIV antigens to dendritic cells using monoclonal antibodies fused to HIV antigens. Antitope is to produce cell lines for the manufacturing of two anti-CD40-HIV fusion proteins which the research institutes are developing as potential therapeutic and prophylactic vaccines to treat HIV.
The cell lines are to be manufactured using Antitope's Composite CHO technology.
"This project further extends our relationship with Baylor in developing a range of therapeutic vaccines for the treatment of diseases such as HIV," said Abzena Chief Scientific Officer Matthew Baker.
Abzena shares were untraded on Monday, having last traded at 81.60 pence.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
